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ABSTRACT  
Purine and pyrimidine nucleotides are important for both biosynthetic and regulatory 
pathways in cells. As constituents of the DNA and RNA molecules, the requirements for 
nucleotides in actively dividing cells are increased. Therefore, the enzymes from the purine 
and pyrimidine nucleotide synthesis pathways are considered attractive targets for treatment 
of diseases associated with deregulated cell proliferation, such as cancer. Dihydroorotate 
dehydrogenase (DHODH), an enzyme from the de novo pyrimidine ribonucleotide synthesis 
pathway located on the inner mitochondrial membrane, has been intensively studied in the 
past few years as a target for anti-cancer therapy. As a result, several inhibitors of DHODH 
are currently in clinical trials for treatment of myeloid malignancies.  
In a screen for p53 activators, we discovered a novel class of DHODH inhibitors with a 
tetrahydroindazole core structure (Paper I). The hit compound from the screen, the chiral 
compound named HZ00, increased p53 translation without increasing p53 mRNA levels or 
the stability of the protein. Furthermore, treatment with HZ00 accumulated cancer cells in 
the S-phase of the cell cycle while it led to cell cycle arrest in normal fibroblasts. After 
screening of commercially available HZ analogues, we discovered the more potent 
compound HZ05. The active enantiomer of the chiral HZ compound was the (R)-enantiomer, 
confirmed by the co-crystallization of DHODH with HZ05 where only (R)-HZ05 was bound 
to the quinone tunnel of DHODH (membrane binding domain). Additionally, both 
compounds acted synergistically with the MDM2 inhibitor nutlin-3 (which protects p53 from 
degradation) in different tumor cell lines and in a melanoma xenograft model.  
Following the discovery of the HZ compounds as inhibitors of DHODH, we investigated the 
structure and function of DHODH using mass spectrometry and molecular dynamics 
simulations (Paper II) and afterwards optimized the HZ compounds in a structure activity 
relationship study (SAR, Paper III). Using non-denaturing mass spectrometry, we 
established that the interactions between DHODH and its co-factor FMN, the lipids present 
in the mitochondrial membrane, as well as ligands such as the DHODH inhibitor brequinar, 
have stabilizing effect on the protein. Furthermore, molecular dynamic stimulations 
demonstrated the flexibility of the membrane binding domain and the transmembrane helix. 
We also illustrated that the lipid interactions that stabilize the membrane binding domain may 
affect the binding of longer ligands, which is important for the design of new inhibitors. The 
optimization of the HZ-compounds was based on a metabolic soft spot study and the crystal 
structure of DHODH with (R)-HZ05 obtained in Paper I. The activity of many of the new 
HZ inhibitors was improved in the in vitro enzymatic assay as well as in cellular assays using 
a melanoma cell line. Based on in vitro metabolic stability analysis we identified a lead 
compound in the series, which demonstrated high specificity towards DHODH. The new 
active HZ-analogues were also able to trigger p53 transcription factor function and affected 
the cell growth/viability of a melanoma cell line with only a small effect on a normal 
fibroblast, suggesting a reasonably wide therapeutic window. Supplementation with an 
excess of uridine ameliorated both, the activation of p53 by the HZ compounds and their 
effect on cell growth/viability. Under our experimental conditions, the new HZ analogues did 
not activate DNA damage markers.  Additionally, we demonstrated that the ability of 
DHODH inhibitors to induce apoptosis related g-H2AX was prevented by co-treatment with 
the pan-caspase inhibitor Z-VAD-FMK.  
Due to the re-emerging interest in DHODH as a drug target, we investigated the early events 
triggered after inhibition of this enzyme (Paper IV). For that purpose, we performed RNA 
sequencing analysis of cells treated with two DHODH inhibitors for up to 4 h. One of the 
earliest significant changes was the fast downregulation of PNUTS mRNA. This event was 
observed at the protein level as well. The PNUTS decrease was accompanied by an increase 
of p53 protein, although the correlation between the two changes requires further 
investigation. Nevertheless, due to the early decrease in PNUTS we propose that the 
downregulation of PNUTS mRNA may be a marker for DHODH inhibition.  
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1   INTRODUCTION  
1.1   NUCLEOTIDE  METABOLISM  
1.1.1   Nucleotides  
Nucleotides are molecules comprised of a base (a nitrogen containing ring), a pentose (a five-
carbon sugar) and one to three phosphate groups (Figure 1a). Depending on the pentose, the 
nucleotides are divided into ribonucleotide (RNA) or deoxyribonucleotide acids (DNA). The 
bases are separated into two groups: the bicyclic purines adenine (A) and guanine (G) and 
the monocyclic pyrimidines cytosine (C), thymine (T), and uracil (U) (Figure 1b). The 
number of phosphate groups determines whether the nucleotides are mono- (NMP), di- 
(NDP), or triphosphates (NTP) respectively [1].  
 
 
Figure 1. Structures of nucleotides and nuclear bases. A structure of uridine monophosphate (UMP) as 
an example of a nucleotide structure. (a) UMP contains the pentose ribose, the nuclear base uracil and one 
phosphate. The base and pentose are forming a nucleoside. Structures of the (b) purine and (c) pyrimidine 
bases.   
 
1.1.2   The  role  of  nucleotides  and  nucleosides  in  cells  
Nucleotides have various functions in the cell, with the most prominent one being their role 
as subunits of the deoxyribonucleic acid (DNA) or ribonucleic acids (RNA) [1]. Containing 
the genetic information of a cell, however, is not the only role of the nucleotides. The covalent 
bonds between the phosphate groups of the NTPs contain high energy which is used in 
various cellular processes and makes these molecules convenient temporary energy carriers 
[1, 2].  Among the nucleotides, ATP (adenosine 5’-triphosphate) is considered the main 
energy source in cells. The hydrolysis of ATP to ADP is used to fuel different cellular 
processes, such as the phosphorylation of creatinine to creatinine phosphate (CP) in cells with 
high energy demands, the initial stages of glycolysis, fast axonal transport, and ion transport 
through active transporters [2-5]. The hydrolysis of GTP (guanosine 5’-triphosphate) by 
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GTPases also provides energy for numerous cellular processes such as regulation of signal 
transduction pathways, protein translation, proliferation, differentiation, and vesicular traffic 
[2, 6, 7]. Protein glycosylation is another process that requires hydrolysis of nucleotides. The 
formation of UDP-sugars, or sugar activation, requires the hydrolysis of UTP [8]. Similar to 
the synthesis of UDP-sugars, the synthesis of membrane phospholipids depends upon 
hydrolysis of CTP [9, 10]. Furthermore, cyclic NMP (cNMPs) cAMP, cGMP, cUMP, and 
cCMP function as second messengers [11, 12], and extracellular NTPs can activate different 
cellular functions through binding to purino- or pyrimidinoreceptors [13]. In addition to the 
numerous functions of the nucleotides, a recent study has shown that ATP can function as a 
hydrotrope and thus stabilizes proteins [14]. The diverse functions of nucleotides in cells 
require continuous regulations of their cellular levels through coordinated synthesis by the 
de novo and salvage synthesis pathways.  
 
1.1.3   Nucleotide  synthesis  pathways  
The cellular nucleotide pools are maintained by two nucleotide synthesis pathways: the de 
novo and the salvage pathways. The de novo pathway uses simple molecules, such as amino 
acids and sugars, for the synthesis of the final NMP products. The salvage pathways rely on 
the degradation of DNA and RNA, the conversion between products from the pathway, as 
well as the import of intermediates or final products from the pathway [15]. 
 
 
Figure 2. Schematic representation of the de novo 
and salvage purine synthesis pathways. The 
abbreviations used in the scheme are: phosphoribosyl 
pyrophosphate amidotransferase (PPAT); Glycinamide 
Ribonucleotide Transformylase (GART); 
Phosphoribosyl formylglycinamidine Synthase 
(PFAS); Phosphoribosyl aminoimidazole Carboxylase 
And Phosphoribosyl amino-
imidazolesuccinocarboxamide Synthase (PAICS); 
Adenylosuccinate Lyase (ADSL); 5-Aminoimidazole-
4-Carboxamide Ribonucleotide Formyltransferase 
(ATIC); Inosine Monophosphate Dehydrogenase 
(IMPDH); Guanine Monophosphate Synthase (GMPS); 
Adenylosuccinate Synthase (ADSS); hypoxanthine 
phosphoribosyltransferase (HPRT); adenine 
phosphoribosyltransferase (APRT). The figure was 
modified from Villa et al. [16]. All copyrights MDPI 
(2019). 
 
 
1.1.3.1   Purine synthesis pathways 
AMP and GMP are synthesized from inosine 
monophosphate (IMP), a central molecule in 
the de novo purine synthesis pathway. The synthesis of IMP consists of 10 steps carried out 
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by 6 enzymes (Figure 2) [17]. The first step of the pathway is catalyzed by phosphoribosyl 
pyrophosphate amidotransferase (PPAT), which transfers an amide group from glutamine to 
phosphoribosyl pyrophosphate (PRPP) forming 5-phosphoribosylamine, glutamate and 
inorganic phosphate [18]. The multifunctional enzyme glycinamide ribonucleotide 
transformylase (GART) catalyzes three non-sequential steps from the pathway – the 
formation of glycinamide ribonucleotide (GAR; step 2); the formation of N-
formylglycinamide ribonucleotide (FGAR, step 3); and the formation of aminoimidazole 
ribonucleotide (AIR, step 5) [19]. The fourth step of the pathway is catalyzed by 
phosphoribosyl formylglycinamide synthese (PFAS) [17]. The next steps are catalyzed by 
phosphoribosyl aminoimidazole carboxylase / phosphoribosyl aminoimidazole 
succinocarboxamide synthase (PAICS; steps 6 and 7), adenylosuccinate lyase (ADSL; step 
8), and aminoimidazole carboxamide ribonucleotide formyltransferase / IMP cyclohydrolase 
(ATIC; steps 9 and 10) [17, 20]. The salvage pathway includes the enzymes hypoxanthine-
guanine phosphoribosyltransferase (HPRT) and adenine phosphoribosyltransferase (APRT), 
which convert hypoxanthine, guanine and adenine to IMP, GMP, and AMP, respectively 
[17].   
 
 
Figure 3. Schematic representation of the de novo 
pyrimidine synthesis pathways. The abbreviations used 
in the scheme are: Carbamoyl-Phosphate Synthetase 2, 
Aspartate Transcarbamylase, And Dihydroorotase 
(CAD); Dihydroorotate Dehydrogenase (DHODH); 
Uridine Monophosphate Synthetase (UMPS). The figure 
was modified from Villa et al. [16]. All copyrights MDPI 
(2019). 
 
 
1.1.3.2   Pyrimidine synthesis pathways 
Uridine monophosphate (UMP) has a central 
role in both the de novo and the salvage 
pyrimidine nucleotide synthesis pathways as a 
precursor for all pyrimidine nucleotides [21, 22]. 
The production of UMP in the de novo synthesis 
pathway consists of 6 catalytic reactions (Figure 
3). The first three steps of the pathway are 
catalyzed by the multifunctional enzyme 
carbamoyl phosphate synthase, aspartate 
transcarbamylase, dihydroorotase (CAD). 
Through the three consecutive reactions CAD 
converts glutamine and aspartate to 
dihydroorotate [21]. Dihydroorotate is oxidized to orotic acid (OA) in the only redox reaction 
by the enzyme dihydroorotate dehydrogenase (DHODH), the only monofunctional enzyme 
in the de novo synthesis pathway. The last two reactions in the pathway are catalyzed by the 
bifunctional uridine monophosphate synthase (UMPS), which has transferase and 
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decarboxylase functions [15, 21, 22]. The remaining pyrimidine nucleotides - CTP and 
deoxythymidine monophosphate (dTMP) are synthesized by the enzymes CTP synthetase 
(CTPS) and thymidylate synthase (TS) from UTP and deoxyuridine monophosphate (dUMP) 
respectively [22, 23]. The enzymes from the salvage pyrimidine pathway use extra- and 
intracellular uridine or cytidine, and pyrimidine nucleotides as substrates to produce their 
respective nucleosides [24].     
 
1.1.4   Regulation  of  nucleotide  synthesis  
The cellular nucleotide levels are regulated by several mechanisms - allosteric regulation of 
the enzymes, regulation of gene expression, metabolic regulation, and growth-state 
dependent regulation.  
1.1.4.1   Allosteric regulation 
The activity of several of the enzymes from the nucleotide synthesis pathways are controlled 
allosterically through feedback regulation by intermediates or end products. The first step of 
the de novo purine synthesis pathway is regulated allosterically by the levels of the final 
products AMP and GMP. The feedback regulation of this step regulates not only the de novo 
synthesis, but also the purine salvage pathway, as well as the rate of DNA synthesis [25]. The 
first reaction from the de novo pyrimidine synthesis pathway is also allosterically regulated 
by the levels of the final products of the pathway. The activity of the carbamoyl phosphate 
synthase domain of CAD is inhibited by increased levels of UTP that acts as a competitive 
inhibitor of the enzyme substrate ATP [26]. 
1.1.4.2   Regulation of gene expression 
The enzymes from the purine and pyrimidine synthesis pathway are regulated at the 
transcriptional level as well. One of the main regulators for both de novo pathways is the 
transcription factor c-MYC [27-29]. In the study of Liu et al. (2008), the expression of several 
genes from the de novo synthesis pathways were increased following MYC upregulation, 
however only PPAT and DHODH were identified as direct target genes. Additionally, a 
ChIP-PET sequencing indicated that the CAD gene contains c-MYC binding site [28]. Other 
transcription factors, such as HIF-1 alpha, have also been associated with regulation of 
nucleotide synthesis [30]. Furthermore, predictions based on DNA binding motifs have 
identified  numerous transcription factors as potential regulators of the expression of 
nucleotide synthesis related genes [15].   
1.1.4.3   Signaling pathways regulating nucleotide synthesis 
The intricate regulation of nucleotide synthesis is also carried out by several signaling 
pathways (Figure 4). Generally, these pathways regulate cell growth and proliferation, such 
as the MAPK/ERK and the mTORC pathways [16]. 
The MAPK cascade, which includes the RAS/MEK/ERK axis, is activated by cell surface 
receptors in response to different extracellular signals. The activation of the cascade leads to 
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activation of different transcription factors, including c-MYC, which results in sustained cell 
proliferation and evading of apoptosis [31]. Activation of RAS and the MAPK cascade 
maintains the nucleotide pools through upregulation of the de novo synthesis pathways by 
supplying intermediates into it [32-34], or by activation of the enzymes such as CAD [35, 
36].  
 
 
 
Figure 4. Signaling pathways in nucleotide metabolism. Growth signals can activate RAS/ERK 
and mTORC1pathways that can activate CAD and the de novo pyrimidine synthesis. AKT activation 
enhances and AMPK activation decreases PRPP availability for nucleotide synthesis. Tumor 
suppressors are shown in pink, key signaling kinases are shown in light blue, metabolic enzymes are 
shown in orange, and small GTPases in dark blue. 5’phosphoribosyl-pyrophosphate (PRPP); 
phosphoribosyl pyrophosphate synthetase (PRPS); transketolase (TKT); AMP-activated protein 
kinase (AMPK). The figure is from Villa et al. [16]. All copyrights MDPI (2019). 
 
Another signaling pathway that leads to an increase in the de novo nucleotide synthesis is the 
mTORC pathway. Similarly to the MAPK cascade, mTORC activation is associated with cell 
growth and proliferation [37]. Activation of mTORC1 signaling increases the de novo purine 
synthesis through induction of methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), an 
enzyme from the folate cycle [38]. Additionally, activation of the mTORC1 signaling 
increases the de novo pyrimidine synthesis as well. This increase is facilitated by Ribosomal 
protein S6 kinase (S6K), which phosphorylates and activates CAD [39, 40].    
The PI3K/AKT signaling pathway, which is upstream of mTORC, regulates both, the de novo 
and salvage purine nucleotide synthesis pathways [41, 42]. PI3K/AKT pathway is activated 
by growth factors that ultimately lead to cell growth and survival, as well as regulation of the 
cell cycle [43]. The activation of AKT kinase by PI3K affects the de novo purine synthesis 
pathway indirectly through regulation of the activity of the pentose phosphate pathway, and 
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directly by increasing the activity of ATIC. Furthermore, AKT modulates PRPP levels, thus 
affecting the salvage purine synthesis pathway as well [41].  
Activation of signaling pathways can also lead to downregulation of nucleotide synthesis. 
Depending on the growth state of the cells, protein kinase A (PKA) can phosphorylate CAD, 
and thus decrease the rate of the de novo pyrimidine synthesis [44]. In a model proposed by 
Sigoillot et al. (2002), PKA activation is correlated with the MAPK decrease of activity. 
Another protein that down-regulates nucleotide synthesis is the Phosphatase and Tensin 
homolog (PTEN). As antagonist of PI3K, activation of PTEN inhibits the phosphorylation of 
AKT and the following downstream pathways, thus decreasing the purine synthesis [45]. 
Moreover, Mathur at al. (2017) demonstrated that PTEN mutant cells and xenograft models 
are sensitized to treatment with DHODH inhibitors [46]. Another pathway that indirectly 
decreases nucleotide synthesis is the Hippo signaling. The Hippo pathway is responsible for 
the regulation of tissue homeostasis and organ development [47], as well as regulating the 
expression of glucose transporters. The decreased glucose uptake reduces the biosynthesis of 
nucleotides [48].  
The importance of balanced nucleotide levels in cells is exemplified by genetic disorders 
caused by alterations in nucleotide metabolism due to mutations in the nucleotide 
biosynthesis genes or in the genes from the regulatory pathways.   
 
1.2   ALTERATIONS  IN  NUCLEOTIDE  METABOLISM  
1.2.1   Inborn  errors  of  nucleotide  metabolism  
Genetic disorders in the nucleotide metabolism genes are rare, but they can lead to disabilities 
and can even be lethal. Treatment options at present are limited, and the disorders are often 
misdiagnosed. The number of known defects in enzymes from the nucleotide synthesis 
pathways and enzymes from the nucleotide catabolism pathway is more than 35, and about 
1/3 of these have severe clinical outcomes. The diseases are developed due to the depletion 
of nucleotides or because of toxicity of intermediate products [49-51].  
1.2.1.1   Inborn errors in purine metabolism 
The inborn errors in purine metabolism are caused mainly by autosomal recessive mutations 
[52], however, mutations in IMPDH1 are autosomal dominant [53]. Defect in several other 
genes, like HPRT and PRPS lead to deficiencies or deficiency/superactivity, respectively [54, 
55]. The symptoms that manifested are heterogeneous, but they could be defined in several 
distinct groups: neurological, immunological, hematological, and renal [49].  
1.2.1.2   Inborn errors in pyrimidine metabolism    
All genetic disorders in the pyrimidine metabolism discovered so far are autosomal disorders. 
Symptoms are diverse, and include immunological, neurological, hematological, renal, 
gastro-intestinal problems, and congenital anomalies [50].  
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1.2.2   Cancer    
1.2.2.1   What is cancer? 
The term cancer is used to describe different malignancies that have a common feature -  
deregulation of cell proliferation caused by genetic mutations that leads to perpetual 
proliferation [56]. In addition to deregulation of cell proliferation, Hanahan and Weinberg 
attributed five more characteristic features of the cancer cells in their article “The Hallmarks 
of Cancer”: evading apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth 
signals, tissue invasion and metastasis, and sustained angiogenesis [57]. Eleven years later, 
these cancer hallmarks were supplemented by four more: deregulation of cellular energetics, 
avoiding immune destruction, genome instability and mutation, and tumor-promoting 
inflammation [58].  
1.2.2.2   Cancer is a genetic disease 
The development of cancer is being widely viewed as a genetic disorder caused by somatic 
or germline mutations. According to the clonal evolution model for tumor formation, 
transformed cells arise from a single mutation that confers a growth advantage (Figure 5). 
Due to their genetic instability, the transformed cells accumulate additional mutations and 
form a heterogeneous cell population. Selective pressure from the local environment allows 
populations with higher variability to circumvent the cell death pathways allowing the 
transformed cells to acquire even more mutations until a tumor is formed [59, 60].  
Mutations that occur in genes important for the growth and proliferation of cells can be 
separated into two categories: proto-oncogenes and tumor suppressor genes. Somatic 
mutations in the proto-oncogenes, like RAS or MYC, have dominant effect that lead to 
increases of their activity and turn them into oncogenes. In contrast, mutations in tumor 
suppressor genes such as TP53, RB1 or PTEN, which regulate cell growth and proliferation 
in normal cells, are usually recessive and require mutations in both alleles [1, 61]. Another 
class of genes with high impact for cancer formation are the genes involved in DNA-repair. 
For example, mutations in MSH2 (MutS homolog 2) or MLH1 (MutL homolog 1) genes can 
lead to genetic instability and result in cancer cells heterogenicity [60].   
 
Figure 5. Genetic instability and heterogeneity drive cancer 
formation. (a) Normal cells have homogenous cell population with low 
or no genomic instability. (b) Tumor precursor cells with mutations that 
increase their genetic instability can form diverse cell populations. 
Selective pressure allows some of these cells to continue to proliferate by 
overcoming the selection barrier. The genetic diversity of these cells 
permits accumulation of additional mutations, higher heterogeneity, and 
ultimately tumor formation. (c) Cells with extensive genome damage 
activate the cell death pathways or the immune system. The cell diversity 
is decreased due to increased cell death or cell cycle arrest; therefore, the 
tumor precursor cells cannot pass the selective barrier. The figure is taken 
from Cahill et al. [60] and re-printed with permission of publisher. 
Copyright Elsevier (1999).   
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1.2.2.3   Cancer as a metabolic disease  
Cancer has also been considered a metabolic disease due to the changes in cellular energetics 
(Figure 6). This notion is not a new one, as Otto Warburg’s theory from 1956 on tumor 
formation was based on the irreversible changes in the cellular respiration and the following 
substitution with fermentation (glycolysis) as the cells’ energy source [62]. Recently, the 
interest towards cancer metabolism has increased and deregulated cellular energetics was 
listed as one of the hallmarks of cancer [58, 63].      
Some of the metabolic changes induced in cancer cells are the overexpression of the enzymes 
from the glycolytic pathway, as well as an increase in the amount of glucose importers, such 
as GLUT1 [64, 65]. Furthermore, tumor cells have increased activity and levels of lactate 
dehydrogenase (LDH), and increased secretion of lactic acid (LA) [66]. Other metabolic 
changes include truncated tricarboxylic acid (TCA) cycle, which provides intermediates for 
anabolic pathways, and changes in cell signaling pathways linked to cellular metabolism [67-
69].  
In addition to the changes in metabolism of the tumor cells, the cells that surround the tumor 
(tumor stroma) also display metabolic alterations. In some tumors, the cancer associated 
fibroblast (CAFs) may adopt glycolysis as a main energy source and provide the tumor cells 
with intermediate metabolites. This metabolic change is referred to as reverse Warburg effect 
[70, 71].  
The metabolic changes in cancer cells resulting from overexpression of metabolic enzymes, 
are induced by deregulation of tumor suppressors and oncoproteins, which regulate the 
nucleotide synthesis pathways as well. 
 
 
 
Figure 6. Changes in metabolic pathways in cancer cells. Glycolysis and tricarboxylic (TCA) cycle are 
altered in cancer cells. The pyruvate produced during glycolysis is converted by lactate dehydrogenase (LDH) 
to Lactic acid (LA) and exported from the cells. Intermediates from glycolysis pathway are used for nucleotide 
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synthesis. Intermediates from the TCA cycle are used to fuel anabolic processes associated with cell growth 
and proliferation. Changes of enzyme activity in cancer cells are indicated with arrows pointing up (activation) 
or down (inhibition). Metabolic changes induced upon activation of the hypoxia-inducible factor 1 (HIF-1a) 
are shown in red. Abbreviations used in the figure: carbonyc anhydrase (CA); carnitine palmitoyltransferase 
(CPT); glucose transporter (GLUT); glutathione (GSH); hexokinase (HK); oxidative phosphorylation 
(OXPHOS); L-type amino acid transporter (LAT1); LDH isoform A (LDHA); monocarboxylate transporter 
(MCT); pyruvate dehydrogenase (PDH); pyruvate dehydrogenase kinase (PDK); phosphofructokinase (PFK); 
phosphoglycerate mutase (PGM); pyruvate kinase isoform M2 (PKM2); pentose phosphate pathway (PPP); 
transketolase (TLK); voltage-dependent anion channel (VDAC). The figure is taken from Kroemer and 
Pouyssegur [67] and re-printed with permission of publisher. Copyright Elsevier (2008). 
    
1.2.3   Deregulation  of  nucleotide  biosynthesis  in  cancer  cells  
As described in 1.2., cancer cells proliferate continuously due to mutations or epigenetic 
changes that keep the proliferation pathways active. Therefore, tumor cells require constant 
supply of nucleotides, which is achieved by stimulation of the nucleotide synthesis pathways 
by oncoprotein activation or tumor suppressor inactivation.      
1.2.3.1   Oncogenic activation of the RAS signaling pathway 
Rat sarcoma gene (RAS), a GTPase that transduces signals from the cell surface membrane 
receptors to the effector cascades in the cytoplasm, is encoded by three genes in the human 
genome: HRAS, NRAS and KRAS [72]. The oncogenic activation of RAS is due to mutations 
in RAS genes, which prevent the hydrolysis of GTP or reduce the affinity for GTP and GDP 
[73]; however, through digital genome scanning, RAS amplifications were discovered in 
colorectal cancer cells as well [74].  
Upon oncogenic activation, RAS can trigger several signaling pathways, including PI3K and 
the MAPK pathways resulting in cell proliferation. Furthermore, through activation of the 
transcription factor HIF-1a and mTOR pathway, RAS activation can indirectly increase 
nucleotide biosynthesis [72]. Additionally, the oncogenic activation of KRAS associated with 
inactivation of the tumor suppressor LKB1 (liver kinase 1) increased the pyrimidine synthesis 
pathway through activation of the mitochondrial Carbamoyl-Phosphate Synthetase (CPS1), 
which indicates that KRAS can supply intermediates for the de novo pyrimidine pathway 
[75].  
 
1.2.3.2   Oncogenic activation of PI3K/AKT/mTORC pathway 
The PI3K/AKT/mTORC pathway regulates various cellular processes associated with 
increased cellular proliferation and enhanced cellular metabolism, including protein 
synthesis, nucleotide synthesis, as well as expression and translocation of glucose 
transporters [76, 77]. Oncogenic activation of the pathway can be due to mutations, 
amplification, or deregulation of any of the proteins in the signaling cascade.  
Phosphoinositide 3-kinase (PI3K) phosphorylates phosphatidylinositol 2-phosphate (PIP2) 
to phosphatidylinositol 3-phosphate (PIP3) upon activation by RAS-related proteins, 
receptor-coupled tyrosine kinases or heterotrimeric G-proteins [76]. In different cancers, 
PI3K is activated by gene amplification [78] or by gain of function mutations in the catalytic 
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p110a domain or in two hotspot regions that prevent inhibition or activate the kinase without 
stimuli, respectively [76, 79-81]. Upon activation PI3K can trigger several effector proteins 
simultaneously, such as AKT/PKB (Protein Kinase B), Guanine exchange factors (GEFs) for 
the Rho/Rac/cdc42 GTPases, and TEC tyrosine kinase family, thus affecting cell morphology 
and motility, glycolysis, or B-cell development [76]. Downstream of PI3K, the effector 
protein AKT/PKB can trigger different biological processes that ultimately lead to 
upregulation of cell growth and proliferation and enhanced cell metabolism [77]. The 
oncogene activation of AKT is usually due to gene amplification or overexpression [82], 
however, activation mutations have also been reported [83]. A critical hub in the PI3K/AKT 
signaling pathway is the protein kinase mTOR1/2. Mutant forms of this kinase can lead to 
hyperactivation of the pathway due to preferential substrate phosphorylation, e.g. S6K1, or 
due to disruption of the interaction between mTOR and its inhibitor DEPTOR [84].    
Since mTOR regulates both de novo nucleotide synthesis pathways, though through different 
mechanisms, the oncogenic upregulation of PI3K/AKT/mTORC will result in increased 
synthesis of nucleotides [38, 40, 85, 86]. Furthermore, the increased expression of glucose 
transporters and their translocation to the cell membrane [87] affect the nucleotide synthesis 
pathways as well by providing intermediate metabolites.    
 
1.2.3.3   Oncogenic activation of transcription factor MYC 
The transcription factor MYC is an oncoprotein activated by signals from various signaling 
pathways like MAPK or SMAD [88]. The protein is encoded by MYC,  one of the most highly 
amplified genes in cancers [89],  however, other modifications such as chromosomal 
translocations [90], or mutations that lead to protein stabilization can also result in neoplastic 
transformation [88].  
Oncogenic activation of MYC regulates the pyrimidine synthesis pathway through the 
transcription of CAD [91], enhances glutamine metabolism [92], and coordinates the 
biosynthesis of nucleotides, and proteins through the translation of phosphoribosyl-
pyrophosphate synthase 2 (PRPS2) [93]. Furthermore, all genes from both de novo purine 
and pyrimidine synthesis pathways have been found to be regulated by MYC, though not all 
of them directly [27]. By regulating both cell growth and nucleotide synthesis, MYC 
oncogenic activation supports cell proliferation. 
   
1.3   P53  –  A  REGULATOR  OF  CELL  FATE  
The tumor suppressor p53, now referred to as “a guardian of the genome” [94], was initially 
regarded as an oncoprotein due to its association with Ras and ability to transform cells [95]. 
Further studies of p53 functions, however, indicated that deficiency, inactivation, or 
mutations of the protein result in tumor formation, while the wild type protein is a tumor 
suppressor [96, 97]. The p53 protein belongs to a family of closely related transcription 
factors that includes p63 and p73 [98].     
    
  11 
1.3.1   Structure,  function,  and  regulation  of  p53    
1.3.1.1   Structure of p53 protein 
The active form of p53 is a homotetramer. In humans, each subunit consists of 393 residues 
divided into 5 domains (Figure 7). The N-terminus of p53 consists of two domains: 
transactivation domain (TAD) and a proline rich region (PRR). The central region of the 
protein consists of the DNA binding domain, and the C-terminus consists of the 
tetramerization domain (TET) and a regulatory domain (CT) [99]. 
 
 
 
Figure 7. Structure of p53 domain organization and location of the most common missense mutations. 
The transactivation domain (TAD) and the proline-rich region (PRR) are located within the N-terminus of p53; 
The central domain of the protein contains the DNA binding domain (p53C, DBD); The C-terminus contains 
the tetramerization domain (TET) and C-terminus domain (CD). The most frequent missense mutations found 
in the DNA binding domain in human tumors as indicated above the domain organization diagram.  The figure 
is taken from Joerger and Fersht [99] and re-printed with permission of publisher. Copyright Annual Reviews 
(2008). 
 
The unstructured N-terminus of p53 contains the TAD and the PRR [100]. The TAD is a 
regulatory domain where transcription factors and p53 regulators bind [101, 102]. Notably, 
the p53 negative regulator MDM2 binds to this domain [103]. In contrast, the function of the 
PRR, which is important for protein-protein interactions, is largely unknown [104]. The core 
domain of the protein is the DNA binding domain that recognizes the target DNA sequences. 
Furthermore, this is the domain that is most frequently mutated in tumors [99, 105]. The 
active form of p53 is as a tetramer, and the formation of the tetramer is mediated by the TET 
[99]. The C-terminal (CT) domain of p53 has regulatory functions and it is an area that is 
modified by different post-translational modifications [106]. This domain has a loose 
structure, but upon binding to DNA it can adopt a helical structure and bind unspecifically to 
DNA [100].         
    
1.3.1.2   p53 is a transcription factor 
The main function of p53 in cells is as a transcription factor. The protein is activated by 
different stress stimuli, such as DNA damage, hypoxia, or nucleotide depletion. The stress 
signal is transmitted to mediator proteins, which activate p53 (Figure 8). Upon activation, 
p53 is stabilized and transported to the nucleus where it initiates the transcription of genes 
that amongst other events stop cell proliferation or activate cell death pathways [107].  
One of the main effector proteins induced by p53 is the cyclin-dependent kinase inhibitor 
(CKI) p21WAF1. This protein inhibits the cyclin dependent kinases (CDK2, CDK1, CDK4/6), 
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and thus prevents the G1/ S phase progression of the cells. Furthermore, p21 can induce cell 
cycle arrest by inhibition of the protein proliferating cell nuclear antigen (PCNA), which 
prevents S-phase entry. Different stress signals induce the expression of p21, including DNA 
damage, oxidative stress, and anticancer agents [108]. Recently, another CDK inhibitor, 
p27KIP1, was identified as a p53 downstream effector as well [109]. p27KIP1 inhibits the 
complexes between CDK2 with Cyclin A and Cyclin E, thus blocking the progress towards 
S phase [110, 111].  
As a “guardian of the genome”, p53 is activated by the DNA damage response (DDR) 
mediator proteins that mediate the effects of different DNA damage signals. Depending on 
the extent of the damage and the time necessary for repair, p53 initiates the expression of 
either DNA repair and cell cycle arrest proteins, or proteins involved in the apoptosis pathway 
[112]. The DNA repair effectors include the proteins from the Growth Arrest and DNA 
Damage-inducible 45 (GADD45) family [113] and 14-3-3s family [114]. Proteins from both 
families also sustain the p53 signal through a feedback activation of p53 [113, 114].  
  
 
 
 
Figure 8. p53 signaling pathway. Upon activation, p53 initiates the transcription of genes that can activate cell 
death or cell survival genes, depending on the stress stimuli. The figure is taken from Bieging and Attardi [115] 
and re-printed with permission of publisher. Copyright Elsevier (2012). 
  
If the DNA damage is extensive and cannot be repaired by the cell, p53 activates the cell 
death pathway by enhancing the expression of pro-apoptotic proteins and the expression of 
inhibitors of pro-survival proteins. The induction of p53-dependent apoptosis is associated 
with transcriptional upregulation of BH-3 proteins NOXA (Phorbol-12-myristate-13-acetate-
induced protein 1) [116], PUMA (p53 upregulated modulator of apoptosis) [117], and the 
BCL-2 (B-cell lymphoma) family members BIM (BCL-2 interacting mediator of cell death) 
[118], BAX (BCL-2–associated X protein) [119] and APAF-1 (Apoptotic protease activating 
factor 1) [120]. Furthermore, p53 can interact directly with BAX/BAK (BCL-2 homologous 
antagonist/killer), which results in the permeabilization of the mitochondrial membrane, 
release of cytochrome-c and activation of the caspase cascade [121]. The role of p53 in other 
types of cell death pathways has not been studied extensively, although, p53 induced 
necroptosis [122] and ferroptosis have been reported [123]. The complexity of the p53 
pathway, and the multitude of effector proteins regulated by p53, requires intricate regulation. 
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1.3.1.3   Regulation of p53 
The main regulator of p53 is the E3-ubiquitin ligase mouse double minute 2 (MDM2). Under 
normal cellular conditions, MDM2 (HDM2 in humans) polyubiquitinates p53 and marks it 
for degradation in the proteasome (Figure 9) [124]. MDM2 mainly targets the C-terminal 
Lys residues of p53 [125], however, Lys residues within the DBD were also found to be 
ubiquitinated by the E3-ligase [126, 127]. The MDM2 protein contains a RING domain, 
which is important for the ubiquitin ligase activity towards p53, as well as for MDM2 
autoubiquitination [128]. In addition to the role as a negative regulator of p53, low levels of 
MDM2 are associated with monoubiquitination of the transcription factor, which leads to 
translocation of p53 from the nucleus to the cytoplasm and activation of the apoptosis 
pathway [129]. The interaction between p53 and MDM2 is regulated by another RING 
domain protein, MDMX or MDM4 and by the tumor suppressor p14ARF. MDMX is an 
oncogene that facilitates the ubiquitination of p53 by MDM2, as well as the 
autoubiquitination of MDM2 [130]. Unlike MDMX, p14ARF is a negative regulator of 
MDM2, and by binding to the E3-ligase, it activates p53 [131].  
 
 
 
Figure 9. Posttranslational modifications of p53. The activity of p53 is regulated by different 
posttranslational modification: Ubiquitination (Ub); Phosphorylation (P); Acetylation (Ac); Sumoylation (S); 
Methylation (Me); Neddylation (N8); Glycosylation (O-Glc); ADP-ribosylation (ADP). The figure is taken 
from Kruse and Gu [132] and re-printed with permission of publisher. Copyrights Elsevier (2009).  
 
The interactions between p53 and MDM2 are regulated by other proteins as well. The 
transcription factor Yin Yang (YY1) acts as a protein co-factor, which facilitates the MDM2-
p53 interaction [133]. Another MDM2 regulator is the death domain-associated protein 
(DAXX) that together with the deubiquitinase HAUSP stabilizes MDM2 and prevents its 
auto-ubiquitination and degradation [134]. The ability of MDM2 to interact with and 
ubiquitinate p53 can also be inhibited. The tumor suppressor RASSF1A disrupts the 
interaction between MDM2, DAXX, and HAUSP, thus increasing the autoubiquitination of 
MDM2 and the activity of p53 [135]. Other proteins that lead to inhibition of MDM2 and the 
subsequent p53 increase are the ribosomal proteins L5, L11, and L23 upon ribosomal stress 
[136, 137].  
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Different modifications, such as phosphorylation or acetylation, are also important for the 
regulation of p53 (Figure 9). ATM, ATR, and other kinases activated upon DNA damage, 
phosphorylate the N-terminus of p53. This phosphorylation inhibits the binding of MDM2 
[138]. Furthermore, ATM, using c-Abl as a mediator, can phosphorylate MDM2 leading to 
destabilization of the ligase and its subsequent degradation [139]. Acetylation of the C-
terminal domain of p53 by p300/CBP stimulates the sequence-specific binding to DNA 
[140]. p300/CBP can also regulate the activity of p53 by acetylation of the RING domain of 
MDM2, which prevents p53 ubiquitination [141, 142]. Conversely, deacetylation of p53 by 
the histone deacetylase SirT1, inhibits the sequence-specific binding to DNA [143, 144]. 
The activity of p53 is regulated by other post-translational modifications as well (Figure 9). 
The C-terminus Lys386 is sumoylated, which enhances the transcription factor activity of 
p53 [145, 146]. Another modification at the C-terminus is neddylation of Lys370, -372, -373. 
The Nedd8 conjugation results in suppression of the activity of p53 [147]. The C-terminal 
Lys can be methylated as well. Depending on the methyltransferases and the modified Lys 
residue, the modification can either activate or inhibit the activity of p53 [148-150]. 
 
1.3.2   p53  mutations  in  cancer  
The TP53 gene is mutated in about 50% of human cancers. The frequent mutations reveal 
the significance of p53 for maintaining genome integrity. Furthermore, the function of the 
protein is impaired indirectly [107]. The majority of the mutations in p53 are point mutations 
that occur in the DNA binding domain, including the hotspot mutations (Figure 7) [105]. 
Mutations in TP53 can result both in loss of function (LOF) as well as in gain of function 
(GOF).  
1.3.2.1   Loss of function mutations (LOF)   
LOF mutations in TP53 may lead to initiation of tumor formation. The mutations can occur 
in the DNA binding domain, which interferes with the tumor suppression functions of p53; 
The mutations can also interfere with the conformation of the protein [151, 152]. Germline 
LOF mutations cause Li-Fraumeni syndrome (LFS), a genetic disease related to early onset 
of cancer [153, 154].    
1.3.2.2   Gain of function mutations (GOF) 
Not all missense mutations of TP53 lead to loss of p53 activity, instead some p53 mutants 
can function as oncoproteins. Therefore, p53 GOF mutations have been associated with 
increased cell proliferation and metastasis formation, higher genomic instability, and 
promoting cancer metabolism [155]. An example of GOF mutations are LFS families with 
mutant p53, which have cancer incidence at earlier age compared to the LFS families with 
loss of function p53 mutation [156].  
The oncoprotein function of mutant p53 is achieved through different mechanisms. Some 
p53 mutants, such as R175H, inhibit the activity of MDM2 and the p53 family member p73, 
while also restoring the activity of p63 [157]. Furthermore, mutant p53 can interact with 
DNA motifs that affect chromatin structure and promote DNA unwinding [158]. The 
  15 
unspecific binding could also explain the ability of mutant p53 to promote the transcription 
of cell growth promoting proteins like vascular endothelial growth factor receptor 2 
(VEGFR2) [159]. Among the expanded functions of mutant p53 is the effect on cellular 
metabolism through translocation of the glucose transporter GLUT1 to the cellular membrane 
[160].     
 
1.3.3   Role  of  p53  in  regulation  of  cellular  metabolism  
Cancer cells have enhanced glucose metabolism, and mutations in p53 can result in 
translocation of glucose transporter and induction of glycolysis, as discussed in 1.2.2.3. and 
1.3.2.2., respectively [64, 160]. These effects are in contrast with the functions of the wild 
type protein, which represses glycolysis directly by inhibition of glucose transporters 
expression [161], or indirectly by affecting the activity of Parkin [162] or NF-kB [163]. 
Additionally, p53 promotes oxidative phosphorylation in the mitochondria [164], and it 
reduces the levels of pyruvate dehydrogenase kinase-2 (PDK2) [165], thus affecting the TCA 
cycle.  
p53 is involved in the regulation of other metabolic pathways. For example, p53 
downregulates lipid synthesis through inhibition of FASN [166, 167], and iron homeostasis 
by regulation of the iron-sulphur cluster assembly enzyme (ISCU) expression [168]. 
Furthermore, p53 is involved in the regulation of the serine metabolism and the associated 
nucleotide metabolism [169, 170]. The transcription factor can also repress the expression of 
GMPS through the activation of p21 [171]. In response to DNA damage, however, p53 can 
orchestrate the metabolic switch necessary for synthesis of new nucleotides via upregulation 
of the pentose phosphate pathway [172] and RRM2B [173].   
GOF p53 mutations lead to changes in the cellular metabolism. In addition to the changes in 
glucose metabolism [160], mutant p53 promotes glycolysis and lipid biosynthesis [174, 175]. 
Mutant p53 also promotes nucleotide synthesis, by stimulating the expression of nucleotide 
metabolism genes and upregulation of the de novo and the salvage pathways [176]. 
 
1.4   DIHYDROOROTATE  DEHYDROGENASE  AS  A  DRUG  TARGET  
1.4.1   Structure  and  function  of  DHODH  enzymes  
1.4.1.1   Classification of DHODH enzymes 
Dihydroorotate dehydrogenase (DHODH) enzymes are expressed in different organisms and 
grouped into two classes depending on several criteria: enzyme sequence, subcellular 
localization, substrate, and co-factor [177]. Class 1, expressed mainly in Gram positive 
bacteria, includes cytoplasmic enzymes. Based on the structure and the reaction substrate, 
Class 1 is divided into two subclasses: 1A and 1B [177]. The enzymes from Class 1A are 
homodimers that use FMN and flavin adenine dinucleotide (FAD) as co-factor [178, 179]. 
DHODH enzymes from Class 1B are heterotetramers, and the electron acceptor for the 
reaction is nicotinamide adenine dinucleotide (NAD+) [180, 181]. The enzymes from Class 
2 DHODH enzymes are found in prokaryotes as well as in eukaryotes. The proteins are 
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membrane bound monomers or homodimers. In eukaryotes, DHODH is bound to the inner 
mitochondrial membrane, and in prokaryotes the protein is bound to the cytosolic membrane 
[177, 182]. Human DHODH belongs to the Class 2 enzyme family and it is located on the 
outer surface of inner mitochondrial membrane. Substrates and products pass freely through 
the more permeable outer mitochondrial membrane to and from the cytoplasm [183].   
1.4.1.2   Structure of human DHODH 
Human DHODH consists of two domains: a catalytic domain (CAT) and a membrane-bound 
domain. The catalytic domain has a/b-barrel structure, and it contains the active site of the 
enzyme. The membrane bound a-helical domain that forms a tunnel towards the active site 
is also referred to as a quinone tunnel. The two domains are connected through a loop [184]. 
The N-terminus of the protein holds the mitochondrial localization signal, which is followed 
by a hydrophobic sequence that anchors the protein to the membrane [185]. The a-helical 
membrane domain is the binding region for ubiquinone (coenzyme Q10), which is reduced 
during the catalytic reaction. This region is also the binding site for numerous inhibitors [184, 
186]. Several conserved residues are associated with the interactions with ubiquinone: 
Arg136 and Tyr356. These residues are also observed to interact with several known 
inhibitors of the enzyme [184, 187].  
1.4.1.3      Function of human DHODH 
DHODH catalyzes the fourth and only redox step in the de novo pyrimidine synthesis 
pathway - the oxidation of dihydroorotate to orotate, which requires the co-factor FMN as an 
electron acceptor (Figure 10) [21, 22]. The reaction follows a double displacement 
mechanism, where the first product is released before the second reaction starts. The 
oxidation of DHO to OA is accompanied by the reduction of the co-factor FMN. The oxidized 
state of FMN is restored with the second reaction where the substrate is ubiquinone (oxidized 
form) and the product is ubiquinol (reduced form) [177].  
The function of DHODH is linked to 
the mitochondrial respiratory chain 
through the oxidation of the ubiquinol 
released from DHODH by complex III 
[21, 177]. In addition, DHODH is 
physically associated with complex II 
and complex III of the mitochondrial 
respiratory chain, and inhibition of 
DHODH leads to partial inhibition of 
complex III [188]. 
 
Figure 10. Schematic representation of the 
DHODH catalyzed reaction. The figure is 
taken from Rawls et al. [185] and re-printed 
with permission of publisher. Copyrights John 
Wiley and Sons (2001).  
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1.4.2   DHODH  as  a  drug  target  
Human DHODH, similarly to other enzymes from the de novo pyrimidine biosynthesis 
pathway, has been considered as a drug target for diseases associated with increased cell 
proliferation. Numerous inhibitors have been described in the literature so far [24, 189-191], 
and as shown in Paper I, DHODH is a frequent target for small molecules [192]. Several 
inhibitors displayed promising results in cell culture and in vivo as anti-proliferative agents 
for the treatment of rheumatoid arthritis (RA), multiple sclerosis (MS) and different types of 
cancer. As synthesis of nucleotides is essential for viral replication, targeting DHODH is also 
an attractive approach to dampen viral infections [193-195]. At present, only leflunomide 
(Arava®) and its active metabolite teriflunomide (Aubagio®) are clinically approved as 
immune modulating drugs [196, 197]. DHODH inhibitors that are in clinical trials for the 
treatment of myeloid malignancies include BAY2402234 (Clinical trial identifier 
NCT03404726) and ASLAN003 (Clinical trial identifier NCT03451084).    
 
1.4.2.1   Leflunomide and teriflunomide 
Leflunomide is an isoxazole compound that is rapidly metabolized in vivo to the active 
metabolite teriflunomide (Figure 11) [198]. The effect of leflunomide/teriflunomide on 
immune cell proliferation [198, 199] was discovered before DHODH was identified as the 
compound’s target [200, 201]. Leflunomide by itself does not inhibit DHODH in vitro, 
therefore, the observed effect in vivo or in cell extracts is due to the presence of its active 
metabolite [202]. The effect of leflunomide as an immunomodulator was studied in rat and 
mouse animal models [203-205]. The promising results from the animal studies resulted in 
clinical trials of leflunomide as a disease-modifying antirheumatic drug (DMARD) in Europe 
and USA [206-208]. Following the clinical trials, leflunomide was approved for use in the 
clinic for treatment of RA in 1999 under the trade name Arava® [196]. The adverse effects 
observed during the clinical trials were comparable to market available DMARDs such as 
methotrexate or sulphasalazine, however, the following post-market surveillance allowed 
identification of rare and unexpected adverse events [209]. Though some of the adverse 
effects depend on the treatment length and dosage [196, 207-209], animal experiments 
indicated that leflunomide has a teratogenic effect in rats [209, 210]. The adverse side effects 
may be due to the long half-life of the compound (15 – 18 days). Therefore, colestyramine 
or activated charcoals are used for its clearance [209]. Recent studies, however, did not show 
a connection between increased anomalies in women and exposure to leflunomide [211]. The 
active metabolite of leflunomide, teriflunomide, is also used in the clinic for treatment of 
relapsing multiple sclerosis (MS) [212, 213]. In 2012 and 2013 teriflunomide was approved 
for treatment of relapsing remitting MS in adult patients by the Food and Drug 
Administration (FDA) and the European Medicines Agency respectively (EMA) [214].   
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Figure 11. Structures of leflunomide and teriflunomide. 
 
The effect of leflunomide as an immunosuppressive drug in animal models and the approval 
for RA treatment in the clinic resulted in extensive research on its potential use for treatment 
of other diseases. Several clinical trials have associated the efficacy of leflunomide for 
treatment of psoriasis and psoriatic arthritis (PsA). Due to the adverse effects, however, 
leflunomide is currently considered a third line therapy for PsA [215]. Leflunomide has also 
been tested for treatment of viral infections in pre-clinical and case reports studies after organ 
transplantation. The effect of leflunomide in clearing cytomegalovirus (CMV) and BK virus 
nephropathy (BKVN) infections, however, is slower compared to other available anti-viral 
treatments. Therefore, leflunomide is usually administered after an initial treatment with 
approved anti-viral drugs or in combination with drugs that achieve a rapid decrease of viral 
load. To date no double-blind clinical trials have been reported [216-218]. Leflunomide has 
also shown dose dependent results for treatment of herpes simplex virus (HSV) in Vero cells 
[219] as well as regression of HSV-1 and HSV-2 lesions in two HIV infected patients [220, 
221]. The immunosuppressive effect of leflunomide, however, could lead to reactivation of 
other virus infections, such as hepatitis B (HBV) [222].  
The effect of leflunomide as an anti-cancer drug has been investigated as well. In several 
neuroblastoma cell lines, treatment with leflunomide induces S-phase arrest and apoptosis, 
and reduced tumor growth in a xenograft mouse model [223]. These effects, however, could 
be due to inhibition of tyrosine kinases, since higher concentrations of leflunomide inhibit 
kinases such as JAK3 or STAT6 [224, 225]. Additionally, leflunomide inhibits the growth of 
melanoma cell lines and melanoma xenograft models [226]. This effect could also be 
attributed to the inhibition of aryl hydrocarbon receptor since uridine could not rescue the 
effect of the drug [227]. Reduction of cell growth after leflunomide treatment in medullary 
thyroid cancer cells in vitro has also been observed [228]. 
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1.4.2.2   Brequinar 
Brequinar (Figure 12) was discovered through a structure-activity relationship (SAR) study 
as an analogue of quinoline carboxylic acid. The compound showed antitumor activity 
against several cancer cell lines and inhibited the growth of different tumor xenograft models 
[229]. The target of the compound was identified as DHODH several years later, after the 
compound was already approved for Phase 
I clinical trials [230]. The pharmacokinetic 
properties and efficacy of brequinar in solid 
tumors was analyzed in several Phase I 
clinical trials. The treatments, however, did 
not meet the expected results. Due to the 
small cohort of patients and the short 
duration of the treatment, the results were 
deemed as insufficient for conclusions 
regarding the clinical effectiveness of 
brequinar [231-233]. 
Figure 12. Structure of brequinar.  
The efficacy of brequinar was tested in several Phase II clinical trials for treatment of 
different solid tumors as well. Patients with colorectal cancer exhibited high level of adverse 
events and the treatment had not effect [234]. Clinical trials with patients with melanoma and 
squamous-cell carcinoma of the head and neck were not responsive either. The adverse 
events, however, were moderate [235, 236]. Additionally, a moderate effect was observed in 
breast cancer patients [237], however, trials in gastrointestinal and lung cancer patients  
showed tumor regression in less than 10% of the patients [238, 239].  
Despite the poor results of the clinical trials, several studies have investigated the effect of 
brequinar in cancer cell lines and in vivo. Brequinar sensitized breast and lung cancer cell 
lines to TRAIL induced apoptosis after co-treatment with doxorubicin [240]. A study by 
Sykes et al. showed that acute myeloid leukemia (AML) cells with constitutive HoxA9 
expression differentiate after treatment with brequinar. Furthermore, brequinar had effect on 
an in vivo xenograft model, where the treatment reduced the tumor load [193]. The results of 
this study indicate that hematological tumors may be a better target for inhibitors of DHODH 
than solid tumors. The effect of brequinar, and leflunomide, have been tested on melanoma, 
myeloma, and lymphoma cells, with the aim to elucidate the mechanism of DHODH 
inhibitors. The study showed a link between c-MYC decrease and accumulation of cells in 
S-phase in cells sensitive to DHODH inhibition [241]. 
The activity of brequinar as an immunosuppressant has been investigated in vitro and in vivo. 
The observed effects, however, were only partially dependent on DHODH inhibition, since 
supplementation with uridine did not result in full recovery [242]. Brequinar also had an 
effect on CMV in vitro but the effect of the compound has not been tested in vivo [243]. 
Additionally, studies with influenza virus showed that brequinar treatment prevents nuclear 
export of mRNA by the virulence factors [244].  
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1.4.2.3   BAY 2402234 and ASLAN003 
BAY2402234 is a novel and selective DHODH inhibitor, which is currently in a Phase I 
clinical trial for treatment of myeloid malignancies (Clinical Trials Identifier: 
NCT03404726). The compound caused differentiation of several AML cell lines, as well as 
in in vivo AML xenograft and patient derived xenograft (PDX) models. Furthermore, 
BAY2402234 treatment reduced the tumor burden as a monotherapy in the in vivo models.  
Transcriptional and proteomics analysis after 24 h and 48 h revealed induction of genes and 
proteins associated with differentiation, apoptosis, and genes from the p53 pathway. At the 
same time, there was a negative regulation of MYC target gene expression. Furthermore, the 
proteomics analysis showed that the phosphorylation of several kinases from the MAPK 
pathway, important for AML development, are decreased [245].   
ASLAN003, another compound that is currently in clinical trial (Clinical Trials Identifier: 
NCT03451084) for the treatment of myeloid malignancies, also induces differentiation of 
AML cells in vivo and in vitro. Treatment with ASLAN003 also triggers apoptosis and 
induces differentiation through activation of the transcription factor AP-1 and reduction of 
protein synthesis. In in vivo xenograft models and AML and PDX cell lines, ASLAN003 
increased the survival and prevented the tumor infiltration [246].  
 
1.4.2.4   Perspectives in the field  
Despite numerous studies and clinical trials, the underlying mechanism of the cellular 
response to DHODH inhibition are still largely unknown. The various mechanisms employed 
by the cells to control nucleotide synthesis, and their dysregulation in cancer, could provide 
information about suitable drug combinations depending on the type of tumor. Furthermore, 
elucidation of the cellular response triggered by inhibition of DHODH could contribute to 
identification of tumors susceptible to monotherapy with DHODH inhibitors.  
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2   AIMS  
 
The aims of this thesis were to (i) identify novel small molecules, which are activators of the 
tumour suppressor of p53, elucidate their target and mechanism of action, and optimize the 
molecules; (ii) investigate DHODH as a drug target.  
 
The specific aims of each paper were:  
 
Paper I: Identification of novel small molecule activators of p53 through a phenotypic screen 
as alternative to currently available p53 activators and discovery of their target. 
 
Paper II: Exploring the interactions between DHODH and inner mitochondrial membrane 
lipids, their significance for DHODH function and for the development of novel inhibitors of 
the enzyme.  
 
Paper III: Optimization of the small molecules discovered in Paper I and development of a 
lead compound with potential to be developed as a therapeutic. 
 
Paper IV: Exploring the early cellular responses triggered by inhibition of DHODH by small 
molecules. The identification of these changes may allow to identify cells particularly 
susceptible to treatment with DHODH inhibitors and/or to identify markers of DHODH 
inhibition.   
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3   RESULTS  AND  DISCUSSION  
3.1   DISCOVERY  OF  NOVEL  DHODH  INHIBITORS  WHILE  IN  SEARCH  FOR  
P53  ACTIVATORS  (PAPER  I)  
3.1.1   Screening  for  p53  activators  and  characterization  of  HZ00  
A treatment strategy for tumors with wild type p53 is to activate this tumor suppressor with 
small molecules that either inhibit p53 negative regulators or affect the localization of the 
protein [247]. Aiming to identify novel small molecules activators of p53, we conducted a 
phenotypic screen with two commercially available small molecule libraries. We used two 
reporter cell lines stably transfected with the p53 reporter plasmid pRGC-DFosLacZ: a 
murine fibroblast cell line T22 and the melanoma cell line ARN8, derived from A375 cell 
line. Based on the ability of the compounds to activate p53 in the tumor cells, but not in the 
fibroblasts, we selected a compound with a tetrahydroindazole (HZ) structure that we called 
HZ00 for further characterization and target identification. 
The hit compound HZ00 contains a chiral center. We showed that the active enantiomer in 
our assays was (R)-HZ00. Furthermore, the compound did not have characteristics of a pan 
assay interference compound (PAINS) [248], and showed promising in vitro 
pharmacokinetic properties. Additionally, HZ00 did not increase the levels of several DNA 
damage markers, such as phosphorylated ATM, ATR, CHK-1, or CHK-2 at the timepoints 
tested.   
HZ00 increased p53 levels in ARN8 cells in a dose-dependent manner, but had little effect 
on a human normal dermal fibroblast (HNDF) or on the expression of p53 target genes. 
Furthermore, HZ00 treatment caused a slight increase of p21, in contrast to the MDM2 
inhibitor nutlin-3 [249]. Through a cellular thermal shift assay (CETSA), we discovered that 
MDM2 or MDMX are not a direct target of HZ00, nor did HZ00 stabilize p53 in a 
cycloheximide chase experiment (Figure 13a). Since the p53 mRNA was not significantly 
increased, we analyzed the levels of newly synthesized p53 protein by examining the 
incorporation of 35S-labelled methionine/cysteine, and saw an increase after HZ00 treatment 
(Figure 13b). 
 
Figure 13. Effect of HZ00 on p53 protein levels. (a) ARN8 cells were treated with HZ00 or vehicle control 
(DMSO) for 7 h prior addition of cycloheximide for the indicated time. Protein levels were analyzed by western 
blot. Protein levels decrease was quantified using Adobe Photoshop. GAPDG was used as loading control. (b) 
ARN8 cells were treated 20 µM HZ00, 5 µM nutlin-3, or vehicle control for 5 h 50 min prior labeling with 35S-
Met-Cys for 30 min. Levels of newly synthesized p53 was isolated by immunoprecipitation and detected by 
western blot followed by autoradiography. The figure shows two independent biological experiments.  
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The selectivity of the compounds towards ARN8 cells compared to HNDF cells was also 
shown in an MTT proliferation assay, and a propidium iodide flow cytometry analysis 
revealed that HZ00 treatment of ARN8 cells increased the sub-G1 population. The 
differences in the mechanism of p53 activation between HZ00 and nutlin-3a, increased 
expression of p53 or increased stability respectively, prompted us to test whether the 
compounds will increase the cell death. The effect of the co-treatment in ARN8 xenograft 
models was indeed synergistic. 
  
3.1.2   Target  identification  
After the characterization of the hit compound, we focused on the identification of the HZ00 
target. We started with analysis of the effect of the compound on the cell cycle. A time course 
BrdU/PI flow cytometry analysis revealed that treatment with HZ00 leads to accumulation 
of ARN8 cells in S-phase. Additionally, the HZ00 treatment resulted in reduction of total 
RNA levels and changes in the nucleoli structure.  
Increased p53 and accumulation of cells in S-phase has been associated with nucleotide 
depletion [250]. Therefore, we tested whether supplementation with different purine and 
pyrimidine nucleosides could ameliorate the effect of the HZ00 treatment. Since 
supplementation with uridine rescued the cells, we hypothesized that the target is an enzyme 
from the pyrimidine synthesis pathway. We continued with the target identification by 
supplementation of HZ00 treated cells with intermediate products from the pathway. We 
identified DHODH as the likely target of the compound, since supplementation with orotic 
acid rescued cell growth but dihydroorotate did not.  
To confirm the target, we compared the effect of HZ00 with two known DHODH inhibitors, 
teriflunomide and brequinar, in a cell growth/viability assay as well as their effect on p53 
transcription factor function activation. In both experiments the assays were performed with 
and without supplementation with excess of uridine, which rescued the effect of the 
compounds. 
3.1.3   DHODH  as  a  drug  target  
3.1.3.1   DHODH is a frequent small molecule target 
After DHODH was identified as the target of HZ00, we re-tested the compounds from the 
screen, which activated p53, in an enzymatic assay with purified enzyme. Despite the diverse 
structures, we identified many of the compounds as inhibitors of DHODH. These results 
indicated that DHODH is a frequent small molecule target. 
3.1.3.2   In search of more potent HZ compounds 
We also tested other commercially available HZ analogues. Among the tested HZ 
compounds, HZ05 was the most potent inhibitor of DHODH. Like HZ00, HZ05 also 
possessed a chiral center, and the active enantiomer in the DHODH enzymatic assay, the cell 
growth/viability assay and p53 transcription factor activation assay was (R)-HZ05 (Figure 
14). The co-crystal structure of DHODH with HZ05 confirmed that the bound enantiomer 
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was indeed the (R)-HZ05. Furthermore, we discovered that (R)-HZ05 is bound to the 
transmembrane domain (quinone tunnel) of DHODH, as teriflunomide and brequinar [184], 
thus preventing the electron transfer to ubiquinone. Similar to HZ00, ARN8 cells treated with 
HZ05 accumulated in S-phase. Co-treatment with nutlin-3 in ARN8 cells increased the 
population of cells in sub-G1 and the in vivo anticancer effect. The activity of the compound 
in xenograft models, however, was low compared to HZ00, which could be due to the short 
half-life of the compound.   
 
Figure 14. Characterization of HZ05. (a) Chemical structures of the hit compound HZ00 and its analogue 
HZ05. (b) Effect of HZ05 on p53 transcription factor activity (bars) and cell growth/viability (lines) in ARN8 
cells with or without uridine supplementation. The values correspond to the mean of three technical replicates 
± SD.   
An RNA sequencing analysis of ARN8 cells treated with (R)-HZ00 and HZ05 displayed the 
similarities between the compounds from the HZ series after 5 h treatment. Furthermore, the 
sequencing analysis revealed upregulation of p53 target genes, and repression of genes from 
the p53-DREAM [251] complex.  
 
3.1.4   DHODH/MDM2  inhibition  -­  model  of  action  
The activity of the DHODH inhibitors form the HZ series was tested in several cancer cell 
lines. Among the most responsive ones were the osteosarcoma line U2OS, and two leukemia 
cell lines, MV-4-11 and SIG-M5, where S-phase accumulation and increase of Sub-G1 
population were observed. After assessing the effect of single agent treatments, we analyzed 
the effect of the co-treatment with the MDM2 inhibitor nutlin-3. This combination increased 
the percent of death cancer cells, as previously observed with ARN8 cells, when cells were 
pre-treated with the HZ compound before the addition of nutlin-3. Furthermore, single agent 
treatment and co-treatment had little effect on the cell cycle of HNDF cells used as normal 
cells control. 
Aside from the staggered treatment (pre-treatment with DHODH inhibitors followed by 
addition of MDM2 inhibitor), we also performed experiments where both compounds were 
added simultaneously. From the results of these treatments we hypothesized that inhibition 
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of DHODH leads to accumulation of cells in S-phase with increased levels of p53 (Figure 
15). Treatment of cells at this vulnerable stage of the cell cycle with high level of p53 with 
inhibitors of MDM2 may push cells towards cell death pathways. To test the model, we used 
U2OS cells and first analyzed the levels of p53 in the S-phase population after treatment with 
HZ05 detecting a significant increase of p53. Afterwards, we confirmed the model by 
annexin V/PI staining, which was increased after staggered treatment with HZ05 and nutlin-
3.  
 
Figure 15. Model of action of DHODH/MDM2 inhibitors combination. Treatment with inhibitors of 
DHODH leads to accumulation of cell in S-phase with increased p53 protein levels. Consecutive treatment with 
MDM2 inhibitors leads to cell death of the population in S-phase. 
After the discovery of a new class of DHODH inhibitors, and the identification of a new 
therapeutic model, we focused on studying DHODH as a drug target and the improvement 
of the HZ-series as anti-cancer therapeutics.  
 
3.2   THE  INTERACTION  OF  DHODH  WITH  THE  LIPIDS  FROM  THE  
MITOCHONDRIAL  MEMBRANE  ARE  IMPORTANT  FOR  THE  ENZYME  
FUNCTION  (PAPER  II)  
 
DHODH is a membrane bound protein [184, 185] but the significance of the membrane 
interactions for its function or its pharmacological inhibition have not been investigated. 
Partly, this could be due to the difficulties associated with structural studies of membrane 
bound proteins, such as low stability in detergents [252]. Improvements of the analytical 
methods, however, have provided new tools for investigation of membrane bound proteins, 
for example, native mass spectrometry has been developed for studying membrane proteins 
[253].      
 
3.2.1   Employing  mass  spectrometry  for  investigation  of  DHODH  
interactions  
3.2.1.1   FMN stabilizes DHODH 
To investigate the interactions between DHODH and the mitochondrial membrane proteins 
we adapted non-denaturing nano-electrospray ionisation mass spectrometry (nESI-MS) 
method, previously used for studying membrane proteins. Employing this method, we 
initially analysed the complex between DHODH and its co-factor FMN. The interactions 
between DHODH and FMN were preserved in the gas phase in the solution containing 
  27 
lauryldimethylamine N-oxide (LDAO) for 
micelle formation. Through this method, we 
were able to distinguish the apo-, holo- and 
ligand bound state of the protein. 
Furthermore, we established that the co-factor 
stabilises the protein conformation.  
 
 
 
Figure 16. Strategy for studying DHODH - ligand 
interactions. The interactions between DHODH and 
its co-factor FMN, or ligands such as the DHODH 
inhibitor brequinar, are preserved upon release from 
detergent after collisional activation. This MS method 
allows discrimination between apo-, holo-, and ligand 
bound forms of DHODH.    
 
3.2.1.2   Lipids - DHODH interactions: effect on protein stability 
Prior the MS analysis of the DHODH-lipid interactions, we tested whether phospholipids 
from the mitochondrial membrane will affect the activity of DHODH in an enzymatic assay. 
The three tested lipids, phosphatidyl ethanolamine (PE), phosphatidyl choline (PC), and 
cardiolipin (CDL), increased the reaction rate. The observed increase with all three 
phospholipids, was comparable, which indicated that there is no specific recognition between 
the enzyme and the different types of lipids. In contrast, the nESI-MS analysis showed that 
PE forms fewer complexes compared to CDL and PC. Since the difference between the three 
lipids is in their charged head groups, we concluded that the lipid-DHODH interactions are 
through charged phospholipid head groups and DHODH. We also explored the lipid-protein 
interactions in conditions with increasing PE concentration. The MS peak was observed after 
binding of three PE molecules, pointing to limited interactions between DHODH and the 
lipids from the mitochondrial membrane.    
Finally, we studied the lipid-DHODH binding effect on the protein stability. The thermal 
stability analysis showed that membrane association does not provide additional stability. In 
contrast, increasing concentrations of DMSO (chemical destabilization) revealed that the 
complex between DHODH and PE was more stable compared to the complexes with the 
enzyme co-factor FMN.  
 
3.2.1.3   Effect of ligand binding on DHODH stability 
Similarly to FMN, the binding of ligands to DHODH leads to stabilization of the protein. For 
this analysis, we performed molecular dynamics stimulations (MD) based on the crystal 
structure of brequinar bound to DHODH in the absence of lipids or detergents [184, 187]. 
The all-atom MD stimulations showed that the membrane binding site is flexible, and binding 
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of a ligand result in stabilization of this domain. Furthermore, through the MD stimulations, 
a second flexible, lipid interacting region was identified.  
 
3.2.2   Understanding  the  interactions  between  DHODH  and  the  lipids  from  
the  inner  mitochondrial  membrane  through  molecular  dynamics  
All-atom MD stimulations were also used for analysis of the lipid - DHODH interaction. 
Using PE bilayer model, we studied the position of DHODH within the mitochondrial 
membrane. We discovered that in addition to the interactions between the membrane-binding 
domain with the lipids, an additional flexible region from the protein interacts with the 
membrane. This trans membrane (TM) helix anchors the protein to the lipid bilayer and 
maintains correct orientation of DHODH.  
The charged limited interactions between the lipids and DHODH, and the dynamic lipid 
bilayer structure, provide a potential regulatory mechanism based on the orientation of the 
enzyme. Similar regulatory mechanism is described for other membrane proteins, such as the 
GTPase K-Ras [254]. 
Lastly, we examined the ubiquinone binding site of the protein, which is in the membrane-
binding domain, and is the binding site of small molecule inhibitors of DHODH. The MD 
stimulations showed that the lipids around the membrane-binding site assisted in stabilizing 
the quinone binding site. Due to the size of the ubiquinone molecule, we suggest that parts 
of the molecule interact with the lipids from the membrane. Similar architecture is observed 
in the binding site of complex I from the mitochondrial respiratory chain [255]. Therefore, 
these interactions should be considered in drug design, since they can affect the activity of 
the small molecules.  
 
3.3   OPTIMIZATION  OF  THE  HZ-­COMPOUNDS  SERIES  (PAPER  III)  
 
The DHODH inhibitors discovered in Paper I showed promising results in several cell lines, 
and HZ00 had good in vitro pharmacokinetic properties. Nevertheless, the progress of this 
class of molecules towards in vivo studies requires further medicinal chemistry optimization.  
 
3.3.1.1   Design of new HZ00 and HZ05 analogues 
We based the design of new HZ analogues on a metabolic soft spot identification study with 
(R)-HZ05, and the crystal structure of (R)-HZ05 with DHODH obtained in Paper I. The 
metabolic soft spot analysis suggested that modifications in the Ar1 moiety of the molecules 
could improve the metabolic profile. The co-crystal structure data, on the other hand, 
indicated the major interactions between the HZ-compound and the amino acids from the 
quinone tunnel of DHODH. Therefore, we decided that small Ar1 substituents may be less 
likely to be susceptible to oxidative metabolism. We also aimed to introduce an interaction 
with Tyr356, which is present in several known inhibitors [184, 245]. The modifications at 
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the Ar2 were focused on testing the extension towards the solvent, and potentially the 
introduction of larger substituents.  
3.3.1.2   Activity of the new inhibitors from the HZ-series 
The newly synthesized analogues were tested in in vitro kinetic enzymatic assay that detects 
the colorimetric change of the final electron acceptor 2,3-dichlorophenolindophenol (DCIP). 
The activity of many of the new inhibitors was improved compared to the originally described 
HZ00 and HZ05. The strongest inhibitors among the HZ00 substituents were compounds 30 
with an IC50 = 15 nM, and 38 with an IC50 = 17 nM. The most active HZ05 analogues were 
able to inhibit DHODH at concentrations lower than 5 nM. Compounds 43 (IC50 = 4 nM); 45 
(IC50 = 3 nM); 46 (IC50 = 1.2 nM), and 51 (IC50 = 2.3 nM) were the most active analogues 
from the series.    
3.3.1.3   Solubility, in vitro metabolic stability, and selectivity 
The most active analogues from both HZ-analogue series were selected for analysis of their 
solubility and in vitro metabolic stability. The solubility and human liver microsomes (HLM) 
in vitro metabolic stability of Compounds 30 and 51 were improved compared to their 
respective analogues (R)-HZ00 and (R)-HZ05. The in vitro metabolic stability in mouse liver 
microsomes (MLM), however, was only marginally improved in 51.  
The results suggested that compound 51 have the highest potential for in vivo mouse studies. 
Furthermore, the main candidate for pre-clinical testing demonstrated low activity in a kinase 
screen, thus showing high specificity towards DHODH.    
3.3.1.4   Activity of the compounds in cellular assays 
The ability of the new analogues to induce p53 dependent transcription correlated to their 
activity in the in vitro enzymatic assay. As in paper I, we assessed the activation of p53 
through a CPRG reporter assay. Furthermore, we supplemented the reactions with excess of 
uridine to distinguish between DHODH-related p53 activation and activation of p53 through 
other mechanisms. Some of the highly active compounds caused a decrease in p53 induced 
transcription, however, we expected this decrease to be related to an impairment of cell 
growth/viability.  
The effect of the HZ analogues on the growth and viability of cells was assessed by 
sulforhodamine B assays (SRB) using two cell lines: the melanoma cell line ARN8 and 
human fibroblast cells (HNDFs). The specificity of the compounds was assessed again by 
supplementation with excess of uridine. The effect on the melanoma cell line was stronger 
compared to the fibroblast cells, similarly to the originally described tetrahidroindazoles in 
Paper I. Furthermore, the activity of many of the compounds was improved or similar 
compared to HZ00 and HZ05. The analogues with the strongest effect on the growth/viability 
of ARN8 cells from the HZ00 series were 30 and 38, while the most active analogues from 
the HZ05 series were compounds 43, 45, 46, and 51. These results correspond to the 
inhibitory activity in the in vitro enzymatic assay. The effect of several of the compounds, 
however, was not recovered at high compounds concentrations, which may be caused by off 
target effects.  
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3.3.1.5    Inhibition of DHODH increases apoptosis induced g-H2AX 
After the analysis of p53 transcription factor activity, and the overall effect of the HZ-
analogues on cell growth/viability, we evaluated the protein level changes by western blot 
analysis. We checked the changes in the levels of p53, p-Ser15, H2AX, as well as g-H2AX 
after supplementation with uridine after 24 h treatment with several of the HZ05 analogues 
and brequinar, used as a reference compound. The treatments increased p53, phosphorylated 
p53, and g-H2AX, however, the uridine supplementation restored the protein levels to those 
of the vehicle control. g-H2AX increase could be due to DNA damage [256, 257] or due to 
induction of apoptosis [258, 259]. Furthermore, g-H2AX increase after treatment with 
DHODH inhibitors have been shown in two studies, and it has been related to both DNA 
damage [46] and apoptosis [260]. However, uridine supplementation was not tested in neither 
of these studies.   
To determine which alternative is prevailing in our assays, we tested two DNA damage 
markers, p-CHK-1 and p-CHK-2. Neither of these markers were affected by inhibition of 
DHODH. To analyze whether g-H2AX is increased due to induction of apoptosis, we 
examined the protein levels after addition of the pan caspase inhibitor Z-VAD-FMK [261]. 
Addition of Z-VAD-FMK reduced the induction of g-H2AX, as well as cleaved PARP, but 
had no effect on p53, p-Ser p53, Bax, or Bcl-2, which are located upstream of the caspase 
cascade. We confirmed that inhibition of DHODH triggers the apoptosis response through 
live cell imaging assays, using a fluorescent caspase 3/7 substrate.   
Taken together, the lead compound from this structure activity relationship study, 51, showed 
suitable solubility and in vitro HLM metabolic stability. The half-life in MLM, however, 
indicates that the series might need additional optimization for development of a clinical 
candidate.    
 
3.4   MECHANISM  OF  DHODH  INHIBITION  (PAPER  IV)  
Numerous potent and specific DHODH inhibitors were discovered in the last few years [192, 
245, 246], however, the mechanism that triggers the cellular response is still not well 
understood. With the aim to identify the early events triggered by the inhibition of DHODH 
that ultimately result in cell cycle arrest [250], apoptosis [223], or cell differentiation [193], 
we performed a time course RNA sequencing.  
3.4.1.1   DHODH inhibition downregulates genes regulating chromatin dynamics 
The RNA sequencing analysis of the melanoma cell line ARN8 revealed that the early 
cellular response after treatment with two DHODH inhibitors, SLL391 (compound 51 in 
Paper III) and brequinar, is downregulation of the differentially expressed genes. The gene 
expression changes caused by both compounds were consistent, which indicated that the 
observed differences were not due to off target effects of the compounds. The initial changes 
were mainly in histone mRNAs. This indicates that the treatments lead to modification of 
chromatin dynamics and drive additional alterations in gene expression, which are either a 
consequence or a cause for changes in the cell cycle profiles. Treatment with DHODH 
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inhibitors leads to accumulation of ARN8 cells in S-phase, therefore, these changes are 
expected [192, 250]. Consistent with these results, the gene ontology (GO) analysis of 
molecular functions showed downregulation of RNA polymerase function, chromatin 
binding, and DNA binding, as well as downregulation of processes such as gene silencing.  
In the later time points (3 and 4 h) the number of upregulated genes started to increase as 
well. Among the biological processes identified in the GO analysis were positive regulation 
of the intrinsic apoptotic pathway and cellular response to chemical stimuli. The upregulated 
differentially expressed genes between the two inhibitors had lower similarity compared to 
the downregulated genes.   
3.4.1.2    Inhibition of DHODH downregulate PNUTS expression 
Of the genes significantly downregulated at an early time point (2 h after treatment with 
SLL391, and 3 h after treatment with brequinar), was the protein phosphatase 1 nuclear 
targeting subunit (PNUTS, PPP1R10). This protein is a negative regulator of the activity of 
protein phosphatase 1 [262, 263]. Therefore, PNUTS regulates important regulators of the 
cell cycle and cellular stress response [264-266].  
The sequencing data was initially validated at mRNA levels by qRT-PCR, and the fold 
change reduction in gene expression was consistent with the sequencing data. Afterwards, 
we checked whether the mRNA changes correspond to protein changes by western blot 
analysis. The PNUTS protein levels were reduced, however, the decrease was observed after 
longer treatments. The decrease of PNUTS coincided with an increase in p53 protein levels, 
both changes were time-dependent. Furthermore, the levels of p53 raised after increasing the 
compound concentration. Changes of compound concentration, however, did not affect the 
level of PNUTS in our experimental conditions.   
In contrast to our data, positive correlation between p53 and PNUTS have been reported 
under hypoxic conditions [265]. However, DHODH inhibition can induce cell death in p53 
deficient cell lines as well, which indicates that the correlation observed under our 
experimental conditions may be cell line specific [245]. Additionally, PNUTS 
downregulation has been associated with apoptosis in a p53-independent manner [265], with 
modulation of the cell cycle progression through Rb1 phosphorylation [264, 267], with c-
MYC downregulation [266], and with control of transcription by RNA Pol II [268]. Due to 
the various cellular processes regulated by PNUTS and the association of some of PNUTS-
modulated proteins with nucleotide synthesis regulation [16], the significance of this change 
requires further investigation. In any case, the fast and significant change in PNUTS mRNA 
levels, may be a hallmark of DHODH inhibition and a useful biomarker of drug activity. 
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